Takeda's antibody-drug conjugate (ADC) and Adcetris (Brentuximab) are now available in combination with chemotherapy during the first-line administration of patients with non-Hodgkin lymphoma and Hodgkin lymphoma.

The HIRA announced on the 17th that the revised bill 'Details on the criteria and methods for applying medical care benefits to drugs prescribed and administered to cancer patients' was released and that opinion inquiry will be conducted by the 25th. The scheduled enforcement date is April 1. The revised bill of this announcement contains the new and changed reimbursement standards for combination therapy including Adcetris, a lymphoma treatment.

◆Non-Hodgkin's lymphoma=